Glanbia plc (LON:GLB - Get Free Report) insider Thomas Phelan acquired 1,558 shares of the business's stock in a transaction dated Monday, May 12th. The stock was acquired at an average price of GBX 1,151 ($15.29) per share, for a total transaction of £17,932.58 ($23,821.17).
Glanbia Trading Up 3.9%
Shares of GLB stock traded up GBX 0.45 ($0.01) during trading hours on Friday, reaching GBX 11.85 ($0.16). The company's stock had a trading volume of 42,433 shares, compared to its average volume of 44,220. The stock has a market capitalization of £3.02 billion, a P/E ratio of 23.50, a P/E/G ratio of 8.32 and a beta of 0.47. Glanbia plc has a one year low of GBX 9.10 ($0.12) and a one year high of GBX 19.62 ($0.26). The firm's fifty day simple moving average is GBX 10.56 and its 200 day simple moving average is GBX 12.74. The company has a current ratio of 1.63, a quick ratio of 0.86 and a debt-to-equity ratio of 48.90.
Glanbia Increases Dividend
The firm also recently disclosed a dividend, which was paid on Friday, May 2nd. Stockholders of record on Thursday, March 20th were given a €0.23 ($0.26) dividend. This is a positive change from Glanbia's previous dividend of $0.16. This represents a dividend yield of 2.18%. The ex-dividend date was Thursday, March 20th. Glanbia's dividend payout ratio (DPR) is currently 7,340.94%.
About Glanbia
(
Get Free Report)
We are a better nutrition company, home to consumer brands and ingredients that help people around the world feel strong, nourished, and to perform well at any age. Everything we do has real nutritional benefit. Everything we do is in pursuit of better, for each other and the planet.
Featured Articles
Before you consider Glanbia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glanbia wasn't on the list.
While Glanbia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
